Clinical Trial Update: Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease [Phase 3]

View source ↗

Summary

Takeda's Phase 3 trial evaluating intravenous vedolizumab for primary sclerosing cholangitis in patients with inflammatory bowel disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Sclerosing Cholangitis

Drugs mentioned

• Entyvio (vedolizumab)

Snippet

Sponsor: Takeda | Conditions: Primary Sclerosing Cholangitis, Inflammatory Bowel Disease | Phase 3 | Status: WITHDRAWN